

# DDR & PARPi for cancer treatments: Today and Tomorrow

Educational Satellite Symposium during the  
ESMO Symposium on Signalling Pathways  
in Cancer 2017



Friday March 17<sup>th</sup> 2017  
18:30 - 19:30

Tramuntana, Melia Sitges  
Sitges-Barcelona, Spain

Dear Colleagues,

It is with great pleasure we invite you to the educational satellite symposium "DDR & PARPi for cancer treatments; today and tomorrow" on Friday March 17<sup>th</sup> during the ESMO Signalling Pathways Symposium in Sitges-Barcelona.

During this symposium you will be presented with the most up-to-date information regarding the innovative approach of targeted therapy based on inhibiting the DNA damage response (DDR) and PARP inhibition in particular.

We hope that you will be able to join us at what promises to be a highly informative and stimulating educational session.

Professor Charlie Gourley  
The University of Edinburgh, UK

Dr. Mark J. O'Connor  
AstraZeneca, Cambridge, UK

## The Agenda DDR & PARPi for cancer treatments: Today and Tomorrow

- 18:30 - 18:35** Introduction, Prof. Charlie Gourley
- 18:35 - 18:50** PARP inhibitors in ovarian cancer, Prof. Charlie Gourley
- 18:50 - 19:05** PARP inhibitors beyond ovarian cancer, Dr. Judith Balmaña
- 19:05 - 19:20** DDR beyond PARP inhibitors, Prof. Thomas Helleday
- 19:20 - 19:30** Conclusions, Prof. Charlie Gourley and Dr. Mark O'Connor

## The Faculty

### Prof. Gourley MD (Co-Chair)

Chair of Medical Oncology and Honorary Consultant  
in Medical Oncology  
University of Edinburgh Cancer Research UK Centre  
MRC Institute of Genetics & Molecular Medicine  
Edinburgh, United Kingdom

### Dr. Mark J. O'Connor PhD (Co-Chair)

Chief Scientist AstraZeneca  
Cambridge, United Kingdom

### Dr. Judith Balmaña

Medical Oncologist and Head of the High Risk  
and Cancer Prevention Group  
Vall d'Hebron University Hospital  
Barcelona, Spain

### Prof. Thomas Helleday

Professor of Translational Medicine and  
Chair in Chemical Biology  
Karolinska Institutet, SciLifeLab, MBB  
Stockholm, Sweden

This activity has been developed by  
COR2ED, a company in independent  
medical education.

**COR2ED**  
THE HEART OF MEDICAL EDUCATION

AstraZeneca has provided a  
sponsorship grant towards this  
independent programme.

**AstraZeneca**